Psoriasis was less likely to progress to psoriatic arthritis (PsA) among patients treated with interleukin-17 (IL-17) or ...

“Psoriatic arthritis is a complex disease ... Some analysts meanwhile have suggested Tremfya’s biggest challenge will be to stay ahead of Skyrizi, which has been proposed as a ‘best-in ...

UCB’s Bimzelx is firmly on physicians’ radars, with Spherix Global Insights finding that awareness of the drug was tracking ...

Skyrizi meanwhile was first launched in 2019 as a treatment for psoriasis and has since had its indications extended to include psoriatic arthritis ... s Stelara follow-up Tremfya (guselkumab ...

Though the approval of Tremfya for psoriasis and psoriatic arthritis indications in kids ... AbbVie expects sales of its key immunology drugs, Skyrizi and Rinvoq in IBD indications to double ...

AbbVie’s Skyrizi was responsible for the highest TV advertising outlay in pharma in most months of 2024, but 2025 is starting ...

(MENAFN- GlobeNewsWire - Nasdaq) Rheumatologists' perceptions of Bimzelx outperform analogue launches of Rinvoq, Skyrizi, and Tremfya in psoriatic arthritis at the three months post-launch mark ...

Image Source: Zacks Investment Research Tremfya is already approved for plaque psoriasis and active psoriatic arthritis (PsA ... ABBV’s immunology products, Skyrizi and Rinvoq, are performing ...

EXTON, PA, Feb. 13, 2025 (GLOBE NEWSWIRE) -- UCB’s Bimzelx (bimekizumab) is making a strong entrance into the U.S. psoriatic ... and Skyrizi, and JNJ Innovative Medicine’s Tremfya in PsA ...